Patrick Hwu: When patients with solid tumors don’t respond to immunotherapy
Patrick Hwu shared a post on X about a recent paper by Maria Parkhurst et al. published in Nature Medicine, commenting: .
“When patients with solid tumors don’t respond to immunotherapy, what’s missing? Perhaps it’s simply the absence of tumor reactive T cells.
Supporting this hypothesis, the Rosenberg group at the NCI observed tumor regression in some patients with refractory colon cancer following the transfer of TCR-transduced T cells reactive against personalized cancer mutations.
This suggests that solid tumors can respond to immunotherapy if sufficient tumor specific T cells are present and may guide future trials of immunotherapy against solid cancers.”
Authors: Maria Parkhurst, Stephanie L. Goff, Frank J. Lowery, Rachel K. Beyer, Hyunmi Halas, Paul F. Robbins, Todd D. Prickett, Jared J. Gartner, Sivasish Sindiri, Sri Krishna, Nikolaos Zacharakis, Lien Ngo, Satyajit Ray, Alakesh Bera, Ryan Shepherd, Noam Levin, Sanghyun P. Kim, Amy Copeland, Shirley Nah, Shoshana Levi, Neilesh Parikh, Mei Li M. Kwong, Nicholas D. Klemen, James C. Yang and Steven A. Rosenberg.
Source: Patrick Hwu/X
Dr. Patrick Hwu, MD, currently serves as the President and CEO of Moffitt Cancer Center. With a focus on understanding the dynamics between tumors and the immune system, Dr. Hwu’s research has been pivotal in advancing gene-modified T-cell therapy.
He contributed seminal work on the development of the first chimeric antigen receptor aimed at combating cancer. His research portfolio extends to vaccines, adoptive T-cell therapies, and mechanisms of immune resistance.